The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.
October 29th 2024
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Lower Dose ATLG Safer, More Effective in Children With Hematologic Malignancies
A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.
Early Administration of Cytarabine May Improve Survival in Pediatric ML-DS
Administering high-dose cytarabine to children with myeloid leukemia of Down syndrome during the second chemotherapy induction cycle resulted in improved event-free survival and overall survival compared to results observed in previous research studies.
FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy
August 30th 2017The FDA issued a historic approval of the first chimeric antigen receptor (CAR) T-cell therapy, authorizing the use of tisagenlecleucel (Kymriah) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory or in second or later relapse.
Arsenic Trioxide Consolidation Effective in Pediatric Acute Promyelocytic Leukemia
Arsenic trioxide consolidation was effective and safe in newly diagnosed pediatric patients with acute promyelocytic leukemia, allowing a significant reduction in cumulative anthracycline doses
Crizotinib Induces High Response Rates in Pediatric ALCL, IMT
In a small study of pediatric patients with relapsed/refractory ALK-positive anaplastic large cell lymphoma, treatment with 165 mg/m2 of crizotinib (Xalkori) was associated with an overall response rate of 83%
FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer
August 1st 2017The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
ODAC Unanimously Recommends Approval of Tisagenlecleucel for Pediatric ALL
Oncologic Drugs Advisory Committee voted 10-0 today to recommend approval of a biologics license application for tisagenlecleucel (CTL019) for the treatment of patients aged 25 or younger with relapsed/refractory B-cell acute lymphoblastic leukemia.
CTL019 CAR T-Cell Therapy Strides Towards Approval in Pediatric and Young Adult Patients With ALL
June 25th 2017CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.
Late Effects of Childhood Cancers Dropping Along With Intensity of Treatments
June 3rd 2017The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.
Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma
May 10th 2017Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.
BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma
April 17th 2017Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.
CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated
The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.